Acucela announced that the novel investigational visual cycle modulator emixustat hydrochloride failed to reduce geographic atrophy lesion growth rate in the SEATTLE study, according to a company press release. There was no significant difference ... Healio, 4 weeks ago
Acucela Announces Termination of Emixustat Agreement and OPA-6566 Agreement with Otsuka Pharmaceutical, and Postponement of Annual Shareholder Meeting - Benzinga.com, 1 week ago
Acucela terminates Emixustat, OPA-6566 agreement with Otsuka Pharmaceutical - CPhI.cn, 1 week ago
May's top stories: ProMedica began human stem cell trial, Cerulean dosed in Phase l/ll combination trial
US-based companies ProMedica and Stemedica Cell Technologies (Stemedica), along with the family of hockey legend Gordie Howe, have planned to begin a human stem cell trial to advance the treatment of traumatic brain injury (TBI). The three-year ...Drug Development Technology, 2 weeks ago
Hundreds of thousands of people worldwide, who have a disease that can lead to blindness, could have their sight restored after The University of Manchester entered into a technology license with Seattle-based company Acucela Inc. The agreement ...News-Medical.Net, 2 months ago
on your WebpageAdd Widget >Get your members hooked!